Positive data from a phase I/II trial of Biomarin Pharmaceutical Inc.'s experimental therapy for CLN2, a type of the lysosomal storage disorder Batten disease, has the company cruising toward midyear regulatory filings with an eye to gaining approvals for the drug during the first half of 2017.